Risedronate pretreatment does not hamper the anabolic effects of prostaglandin E2 in ovx rats

The influence of dietary sodium on bone development in growing rats

The present study investigated the effects of dietary sodium on bone growth in young rats. Five-week-old rats were fed one of three different diets for 60 days: low sodium (NaCl, 0.32 g/kg diet), normal sodium (NaCl, 2.6 g/kg) and high sodium (NaCl, 20 g/kg). The proximal tibial metaphysis (PTM), the fifth lumbar vertebra (LV5) and the middle part of the tibia shaft (TX) were analysed by bone histomorphometry. The expression of three osteogenesis genes, Runx2, osteopontin and osteocalcin, was determined by RT-PCR in bone samples from the skull. In both the PTM and LV5, trabecular area and thickness were increased by the low-sodium diet, while the high-sodium diet decreased trabecular area in LV5. Dynamic data revealed that sodium restriction increased bone formation parameters in the PTM and LV5, but decreased bone resorption in LV5. In TX, endosteal bone formation was enhanced by the low-sodium diet and depressed by the high-sodium diet compared to the normal sodium group. But there were no statistically changes in the cortical bone area of TX. Low-sodium intake significantly enhanced the expression of all three osteogenesis genes compared to the normal sodium group, while high-sodium intake suppressed osteogenic gene expression. Our results suggest that sodium restriction in growing rats promotes bone development by influencing both bone formation and resorption.

Involvement of oxidative stress in age-related bone loss

BACKGROUND

Age-related bone loss is a primary factor in osteoporosis and osteoporotic fractures in the elderly. Although oxidative stress was reported to play an important role in aging and postmenopausal bone loss, data on relating oxidative stress to age-related bone loss were scanty. This study aimed to investigate whether oxidative stress is involved in age-related bone loss.

MATERIALS AND METHODS

Young, adult, and old male Wistar rats were used in this study. Each group consisted of 26 animals. Oxidative stress parameters, such as advanced oxidation protein products (AOPP), malondialdehyde (MDA), and superoxide dismutase (SOD), were measured in the plasma and right femur homogenates. Bone mineral density (BMD) of left femurs and histomorphometry of tibias were investigated.

RESULTS

In the plasma and femurs, the levels of AOPP and MDA were increased and the SOD activity was decreased with aging. Femur BMD decreased significantly in old rats. Bone histomorphometry indicated decreases in cancellous bone volume, trabecular thickness, percent labeled perimeter, mineral apposition rate, and bone formation rate with aging. The AOPP levels in plasma and femur, and MDA levels in the plasma were negatively correlated with the femur BMD. The SOD activity in plasma and femur was positively correlated with the femur BMD.

CONCLUSIONS

Increase of oxidative stress and bone loss appear with aging. Oxidative stress is involved in age-related bone loss and might play an important role in the pathology of age-related bone loss.

Prevention of bone loss in ovariectomized rats by combined treatment with risedronate and 1alpha,25-dihydroxyvitamin D3

Bisphosphonates inhibit bone loss through inhibition of osteoclast-mediated bone resorption. At low doses, vitamin D metabolites can prevent bone loss in models of osteopenia in rats by an antiresorptive effect, while at high doses they also stimulate osteoblast activity and show an anabolic effect. Therefore, combined therapy with bisphosphonates and vitamin D analogs might be expected to be more effective than either treatment alone. It was the aim of this study to compare the efficacy of risedronate and of the naturally occurring vitamin D hormone 1alpha,25-dihydroxyvitamin D3 (calcitriol), alone and in combination, for the prevention of ovariectomy-induced bone loss in rats. One hundred ten female 4-month-old Sprague-Dawley rats were used for this experiment. Ninety rats were bilaterally ovariectomized (OVX), 10 rats were sham-operated (SHAM), and 10 rats were killed at the time of surgery as a baseline control. Groups of rats (10 rats/group) received vehicle or daily doses of 0.1 mg or 0.5 mg of risedronate or 0.05 microg or 0.1 microg of calcitriol/kg body weight, alone and in combination. Both compounds were administered orally via gavage, commencing on the day after surgery. Although estrogen deficiency-induced bone loss was prevented by individual prophylactic administration of risedronate or calcitriol, OVX rats treated with a combination of risedronate and calcitriol had higher bone mineral density (BMD), cancellous bone area (B.Ar), and bone strength in long bones and vertebrae compared with rats receiving risedronate alone. Furthermore, calcitriol enhanced the suppressive effects of risedronate on osteoclast number and partially counteracted the suppressive effects of risedronate on bone formation and histomorphometric indices of osteoblast team performance. Risedronate did not reduce the anabolic effect of calcitriol, and at the high dose it normalized hypercalcemia in calcitriol-treated OVX rats. Therefore, this study in OVX rats suggests that combined therapy with bisphosphonates and vitamin D analogs may offer advantages over the treatment with bisphosphonates or vitamin D analogs alone.